Role of cancer stem cell markers ALDH1, BCL11B, BMI-1, and CD44 in the prognosis of advanced HNSCC.
Mark JakobKariem SharafMarkus SchirmerMartin LeuStefan KüfferMattis BertlichFriedrich IhlerFrank HaubnerMartin CanisJulia KitzPublished in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2020)
Although validation in independent cohorts is still needed, testing for CSC markers in patients with advanced or late stage HNSCC might be beneficial, especially if many comorbidities exist or disease is irresectable. The findings might guide the development and earlier use of targeted therapies in the future.